DF
GILD icon

DecisionPoint Financial’s Gilead Sciences GILD Stock Holding History

DecisionPoint Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64K Sell
13
-33
-72% -$4.35K ﹤0.01% 343
2026
Q1 		$6.41K Sell
46
-13
-22% -$1.82K ﹤0.01% 206
2025
Q4 		$7.24K Buy
59
+13
+28% +$1.58K ﹤0.01% 221
2025
Q3 		$5.11K Hold
46
– – ﹤0.01% 171
2025
Q2 		$5.14K Buy
+46
New +$4.9K ﹤0.01% 176

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DecisionPoint Financial's GILD Position: Q2 2026 in Review

DecisionPoint Financial reduced its Gilead Sciences (GILD) stake by 72% in Q2 2026, selling an estimated $4.35K and leaving 13 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #343.

DecisionPoint Financial first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.24K in Q4 2025. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • DecisionPoint Financial held 13 shares of Gilead Sciences worth $1.64K as of Q2 2026.
  • DecisionPoint Financial sold 33 Gilead Sciences shares in Q2 2026, an estimated $4.35K.
  • Gilead Sciences made up ﹤0.01% of DecisionPoint Financial's portfolio in Q2 2026, its #343 holding.
  • DecisionPoint Financial first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • DecisionPoint Financial's Gilead Sciences position peaked at $7.24K in Q4 2025.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on DecisionPoint Financial's 13F filing for Q2 2026, filed 5 Aug 2026.